Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 2
1999 1
2004 2
2005 5
2006 5
2007 5
2008 2
2009 6
2010 8
2011 5
2012 7
2013 8
2014 15
2015 17
2016 9
2017 9
2018 8
2019 12
2020 2
2021 6
2022 1
2023 2
2024 5
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Effects of Exercise Training With and Without Ranolazine on Peak Oxygen Consumption, Daily Physical Activity, and Quality of Life in Patients With Chronic Stable Angina Pectoris.
Willis LH, Slentz CA, Johnson JL, Kelly LS, Craig KP, Hoselton AL, Kraus WE. Willis LH, et al. Am J Cardiol. 2019 Sep 1;124(5):655-660. doi: 10.1016/j.amjcard.2019.05.063. Epub 2019 Jun 6. Am J Cardiol. 2019. PMID: 31296368 Clinical Trial.
Ranolazine reduces angina frequency and increases exercise capacity. We hypothesized that exercise training with ranolazine would allow subjects to train at greater intensities, resulting in greater improvements in exercise capacity, physical activity, and health-re …
Ranolazine reduces angina frequency and increases exercise capacity. We hypothesized that exercise training with ranolazine wo …
ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial.
Sinha A, Rahman H, Douiri A, Demir OM, De Silva K, Clapp B, Webb I, Gulati A, Pinho P, Dutta U, Ellis H, Shah AM, Chiribiri A, Marber M, Webb AJ, Perera D. Sinha A, et al. Circulation. 2024 Jan 2;149(1):36-47. doi: 10.1161/CIRCULATIONAHA.123.066680. Epub 2023 Oct 31. Circulation. 2024. PMID: 37905403 Free PMC article. Clinical Trial.
METHODS: Patients with angina with nonobstructive coronary arteries underwent blinded invasive CFR measurement and were randomly assigned to receive 4 weeks of amlodipine or ranolazine. After a 1-week washout, they crossed over to the other drug for 4 weeks; final assessme …
METHODS: Patients with angina with nonobstructive coronary arteries underwent blinded invasive CFR measurement and were randomly assigned to …
Antinociceptive effect of ranolazine and trimetazidine.
Tolunay H. Tolunay H. Expert Rev Cardiovasc Ther. 2021 May;19(5):457-464. doi: 10.1080/14779072.2021.1914589. Epub 2021 Apr 16. Expert Rev Cardiovasc Ther. 2021. PMID: 33823738 Clinical Trial.
In this study, it was aimed to evaluate the antinociceptive effects of ranolazine and trimetazidine.Methods: Sixty patients who were started on trimetazidine or ranolazine treatment were included in the study. ...The decrease in VAS (p = 0.001) and the decrease in S …
In this study, it was aimed to evaluate the antinociceptive effects of ranolazine and trimetazidine.Methods: Sixty patients who were …
[The RIVER-PCI study].
Ferlini M, Borghesi M, Musumeci G. Ferlini M, et al. G Ital Cardiol (Rome). 2017 Oct;18(10):677-681. doi: 10.1714/2790.28256. G Ital Cardiol (Rome). 2017. PMID: 29105681 Clinical Trial. Italian. No abstract available.
Ranolazine effects on exercise tolerance and angina frequency in Taiwanese stable angina: A bridging study of the CARISA randomized trial.
Lee JK, Hsieh IC, Huang PH, Wu YW, Hsu JC, Kuo JY, Chang PY, Wu CH, Hwang JJ. Lee JK, et al. J Formos Med Assoc. 2025 Oct;124(10):931-937. doi: 10.1016/j.jfma.2024.09.018. Epub 2024 Oct 5. J Formos Med Assoc. 2025. PMID: 39370366 Free article. Clinical Trial.
BACKGROUND: The effectiveness of Ranolazine on chronic angina had been proved and launched in the United States. This study aimed to determine whether add-on Ranolazine could also be effective in Taiwanese population with persisting angina symptoms despite taking co …
BACKGROUND: The effectiveness of Ranolazine on chronic angina had been proved and launched in the United States. This study aimed to …
Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers.
Marciniak TA, Serebruany V. Marciniak TA, et al. Am J Med. 2019 Dec;132(12):e844-e845. doi: 10.1016/j.amjmed.2019.02.032. Epub 2019 Mar 11. Am J Med. 2019. PMID: 30871921 Clinical Trial.
BACKGROUND: Ranolazine is an anti-angina agent with many metabolites creating the potential for off-target effects. ...CONCLUSIONS: Ranolazine potentiates the effects of ACEIs and ARBs. Clinicians should monitor for this potentiation when initiating treatment with …
BACKGROUND: Ranolazine is an anti-angina agent with many metabolites creating the potential for off-target effects. ...CONCLUSIONS: …
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, Ben-Yehuda O, Katz A, Jones PG, Olmsted A, Belardinelli L, Chaitman BR. Kosiborod M, et al. J Am Coll Cardiol. 2013 May 21;61(20):2038-45. doi: 10.1016/j.jacc.2013.02.011. Epub 2013 Mar 10. J Am Coll Cardiol. 2013. PMID: 23500237 Free article. Clinical Trial.
We conducted a randomized trial to test the antianginal benefit of ranolazine in patients with diabetes and stable angina. METHODS: TERISA (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) was an international, randomized, double-blin …
We conducted a randomized trial to test the antianginal benefit of ranolazine in patients with diabetes and stable angina. METHODS: T …
Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
Chorin E, Hu D, Antzelevitch C, Hochstadt A, Belardinelli L, Zeltser D, Barajas-Martinez H, Rozovski U, Rosso R, Adler A, Benhorin J, Viskin S. Chorin E, et al. Circ Arrhythm Electrophysiol. 2016 Oct;9(10):e004370. doi: 10.1161/CIRCEP.116.004370. Circ Arrhythm Electrophysiol. 2016. PMID: 27733495 Free PMC article. Clinical Trial.
METHODS AND RESULTS: We performed an experimental study of ranolazine in TSA201 cells expressing the D1790G mutation. We then performed a long-term clinical evaluation of ranolazine in LQT3 patients carrying the D1790G mutation. ...The QT-shortening effect of ran …
METHODS AND RESULTS: We performed an experimental study of ranolazine in TSA201 cells expressing the D1790G mutation. We then perform …
Open-label trial of ranolazine for the treatment of myotonia congenita.
Arnold WD, Kline D, Sanderson A, Hawash AA, Bartlett A, Novak KR, Rich MM, Kissel JT. Arnold WD, et al. Neurology. 2017 Aug 15;89(7):710-713. doi: 10.1212/WNL.0000000000004229. Epub 2017 Jul 14. Neurology. 2017. PMID: 28710329 Free PMC article. Clinical Trial.

EMG of the abductor digiti minimi and tibialis anterior showed significantly reduced myotonia duration (p < 0.001, p < 0.01) at week 4. No participant discontinued ranolazine because of side effects. CONCLUSIONS: Ranolazine appeared to be well tolerated over a

…

EMG of the abductor digiti minimi and tibialis anterior showed significantly reduced myotonia duration (p < 0.001, p < 0.01) at week 4

…
Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial.
Yusuf J, Prakash G, Safal S, Mehta V, Mukhopadhyay S. Yusuf J, et al. Coron Artery Dis. 2024 May 1;35(3):186-192. doi: 10.1097/MCA.0000000000001347. Epub 2024 Feb 20. Coron Artery Dis. 2024. PMID: 38411168 Clinical Trial.
Eligible patients were assigned to either nicorandil (n = 105), ranolazine (n = 105) or control group (n = 105) in 1 : 1 : 1 ratio by block randomization. ...In addition to hydration, patients in nicorandil group received oral nicorandil (10 mg, 3 times/d) and those in …
Eligible patients were assigned to either nicorandil (n = 105), ranolazine (n = 105) or control group (n = 105) in 1 : 1 : 1 ratio by …
126 results